

# The Role of Rapid TTR Knockdown in the Treatment of hATTR Amyloidosis

Join us at an Industry Education Event sponsored by Alnylam Pharmaceuticals during the HFSA Annual Scientific Meeting 2024!

## ABOUT THE PROGRAM\*

Please join our distinguished presenters as they provide an overview of hereditary transthyretin (hATTR) amyloidosis, and discuss the clinical profile of a treatment option for the polyneuropathy of hATTR amyloidosis in adults. Breakfast will be provided. To comply with PhRMA Code guidance, alcohol is not provided at Alnylam programs.

## Speakers



### Amanda Peltier, MD

Associate Vice Chair Academic Affairs  
Division Chief Neuromuscular  
Professor Neurology  
Vanderbilt University Medical Center  
Nashville, TN



### Marcus Anthony Urey, MD

Cardiologist  
Associate Professor of Medicine  
Director, Heart Transplantation  
Director, Cardiac Amyloidosis  
UC San Diego Health  
San Diego, CA

**Saturday, September 28, 2024**

7:15 AM – 8:45 AM ET

**Triumph A Ballroom**  
Signia by Hilton Atlanta

This Industry Innovative Event is not part of the scientific program as planned by the HFSA Program Committee. This event is neither sponsored by nor endorsed by HFSA. This event does not qualify for continuing education credit.

*\*Intended for US Healthcare Professionals only*

© 2024 Alnylam Pharmaceuticals, Inc. All rights reserved. TTR-USA-00393

